Please use this identifier to cite or link to this item:
Title: Axolotl Ambystoma mexicanum extract induces cell cycle arrest and differentiation in human acute myeloid leukemia HL-60 cells
Authors: Suleiman, Sherif
Di Fiore, Riccardo
Cassar, Analisse
Formosa, Melissa Marie
Schembri-Wismayer, Pierre
Calleja-Agius, Jean
Keywords: Ambystoma mexicanum
Natural products
Cell cycle
Cell differentiation
Issue Date: 2020
Publisher: Sage Publications Ltd.
Citation: Suleiman, S., Di Fiore, R., Cassar, A., Formosa, M. M., Schembri-Wismayer, P., & Calleja-Agius, J. (2020). Axolotl Ambystoma mexicanum extract induces cell cycle arrest and differentiation in human acute myeloid leukemia HL-60 cells. Tumor Biology, 10.1177/1010428320954735.
Abstract: Acute myeloid leukemia is the most common form of acute leukemia in adults, constituting about 80% of cases. Although remarkable progress has been made in the therapeutic scenario for patients with acute myeloid leukemia, research and development of new and effective anticancer agents to improve patient outcome and minimize toxicity is needed. In this study, the antitumor activity of axolotl (AXO) Ambystoma mexicanum crude extract was assessed in vitro on the human acute myeloid leukemia HL-60 cell line. The anticancer activity was evaluated in terms of ability to influence proliferative activity, cell viability, cell cycle arrest, and differentiation. Moreover, gene expression analysis was performed to evaluate the genes involved in the regulation of these processes. The AXO crude extract exhibited antiproliferative but not cytotoxic activities on HL-60 cells, with cell cycle arrest in the G0/G1 phase. Furthermore, the AXO-treated HL-60 cells showed an increase in both the percentage of nitroblue tetrazolium positive cells and the expression of CD11b, whereas the proportion of CD14-positive cells did not change, suggesting that extract is able to induce differentiation toward the granulocytic lineage. Finally, the treatment with AXO extract caused upregulation of CEBPA, CEBPB, CEBPE, SPI1, CDKN1A, and CDKN2C, and downregulation of c-MYC. Our data clearly show the potential anticancer activity of Ambystoma mexicanum on HL-60 cells and suggest that it could help develop promising therapeutic agents for the treatment of acute myeloid leukemia.
Appears in Collections:Scholarly Works - FacM&SAna

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.